Syrosingopine sensitizes cancer cells to killing by metformin

Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?

(2016) Navdeep S. Chandel et al.   Cell Metabolism

Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy

(2016) Ryan J.O. Dowling et al.   Cell Metabolism

Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study

(2016) Hongjiang Wu et al.   LUNG CANCER

Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells

(2015) Lucas B. Sullivan et al.   CELL

A Moonlighting Human Protein Is Involved in Mitochondrial Import of tRNA

(2015) Maria Baleva et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2015) Sil Kordes et al.   LANCET ONCOLOGY

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria

(2014) Hannah R. Bridges et al.   BIOCHEMICAL JOURNAL

Metformin: A metabolic disruptor and anti-diabetic drug to target human leukemia

(2014) Célia Rosilio et al.   CANCER LETTERS

Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial

(2014) Konstantinos K. Tsilidis et al.   DIABETES CARE

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

(2014) William W Wheaton et al.   eLife

Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer

(2014) Kevin M. Schuler et al.   Cancer Medicine

LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin

(2013) David B. Shackelford et al.   CANCER CELL

The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells

(2013) Célia Rosilio et al.   CANCER LETTERS

C-Terminal Peptide of γ-Enolase Impairs Amyloid-β-Induced Apoptosis Through p75NTR Signaling

(2013) Anja Hafner Pišlar et al.   NEUROMOLECULAR MEDICINE

Surface α-Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target

(2013) Kuan-Chung Hsiao et al.   PLoS One

γ-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways

(2012) Anja Hafner et al.   BIOCHEMICAL JOURNAL

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study

(2012) Saroj Niraula et al.   BREAST CANCER RESEARCH AND TREATMENT

Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death

(2012) G. Cheng et al.   CANCER RESEARCH

Metformin is synthetically lethal with glucose withdrawal in cancer cells

(2012) Javier A. Menendez et al.   CELL CYCLE

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

(2012) R. J. Stevens et al.   DIABETOLOGIA

α-Enolase, a Multifunctional Protein: Its Role on Pathophysiological Situations

(2012) Àngels Díaz-Ramos et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions

(2012) Susanne A.I. Seidel et al.   METHODS

Passenger deletions generate therapeutic vulnerabilities in cancer

(2012) Florian L. Muller et al.   NATURE

Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis

(2012) Hiroshi Noto et al.   PLoS One

Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning

(2012) Michael N. Pollak   Cancer Discovery

Understanding the benefit of metformin use in cancer treatment

(2011) Ryan JO Dowling et al.   BMC Medicine

α-enolase: a promising therapeutic and diagnostic tumor target

(2011) Michela Capello et al.   FEBS Journal

Gamma-1-Syntrophin Mediates Trafficking of Gamma-Enolase towards the Plasma Membrane and Enhances Its Neurotrophic Activity

(2011) Anja Hafner et al.   NEUROSIGNALS

Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

(2010) A. DeCensi et al.   Cancer Prevention Research

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

(2010) P. D. Home et al.   DIABETOLOGIA

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction

(2010) M Colombi et al.   ONCOGENE

New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes

(2009) G. Libby et al.   DIABETES CARE

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

(2009) Sao Jiralerspong et al.   JOURNAL OF CLINICAL ONCOLOGY

Mysterious Metformin

(2009) C. R. Chong et al.   ONCOLOGIST

Target identification using drug affinity responsive target stability (DARTS)

(2009) B. Lomenick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA